STAAR Surgical

STAAR Surgical shareholders have rejected Alcon’s acquisition bid, empowering the company to pursue independent growth. This decision, heavily influenced by major shareholder Broadwood Partners, allows STAAR to capitalize on its innovative EVO Visian ICL technology and strong market position in refractive error correction. The company faces opportunities and challenges in scaling production and expanding market reach, with a focus on its proprietary Collamer material and future R&D. Broadwood Partners expressed confidence in STAAR’s standalone prospects and commitment to unlocking its full potential.

STAAR Surgical’s special stockholder meeting regarding the Alcon merger has been postponed to January 6, 2026. This decision, initiated by Alcon, delays the vote on the acquisition. STAAR, known for its EVO ICL vision correction technology, faces a complex M&A landscape. Investors are advised to consult SEC filings and the proxy statement for crucial details as the new meeting date approaches.

Alcon and STAAR Surgical announced the postponement of STAAR’s Special Meeting of Stockholders regarding their proposed merger. Originally scheduled for October 23, 2025, it’s now set for November 6, 2025. The record date for voting eligibility remains September 12, 2025. The merger aims to strengthen Alcon’s refractive surgery market position through STAAR’s ICL technology. Analysts suggest regulatory reviews and due diligence contributed to the delay. The combined entity anticipates innovation in intraocular lens technology but faces integration challenges and market competition.

STAAR Surgical (STAA) will release its Q2 2025 financial results on August 6, 2025, after market close. A live webcast and earnings call will follow at 4:30 p.m. ET. The company, a leader in phakic IOLs like the EVO ICL™, aims to reduce dependence on glasses and contacts. STAAR has distributed over 3 million ICLs across 75+ countries. A replay will be available on STAAR’s investor relations website for 90 days.